NCT07390682

Brief Summary

Obstructed defecation syndrome (ODS) is a common functional bowel disorder characterized by difficulty in stool evacuation. Bilateral posterior tibial nerve stimulation (BT PTNS) has emerged as a noninvasive, safe, and effective therapeutic option for functional ODS, improving symptom severity and quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 23, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 5, 2026

Completed
10 days until next milestone

Study Start

First participant enrolled

February 15, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 25, 2026

Completed
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 28, 2026

Completed
Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

1 month

First QC Date

December 23, 2025

Last Update Submit

April 24, 2026

Conditions

Keywords

ObesityBilateral Tibial Nerve StimulationObstructed DefecationODSBT PTNS

Outcome Measures

Primary Outcomes (2)

  • Change in symptom severity measured by the Modified Obstructed Defecation Score (MODS).

    Scale range: 0 to 24 Interpretation: Higher scores indicate more severe obstructed defecation symptoms Unit of measure: Units on a validated symptom severity scale. No aggregation of different measurements into a single reported value is performed. Each scale is analyzed independently. In response to the Advisory Issue, we have included the unabbreviated titles of the scales, their minimum and maximum values, and clarified whether higher scores represent better or worse outcomes for each outcome measure.

    Within 6 weeks of treatment.

  • Change in quality of life measured by the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL).

    Scale range: 0 to 96 Interpretation: Higher scores indicate worse constipation-related quality of life Unit of measure: Mean score on a validated quality-of-life scale No aggregation of different measurements into a single reported value is performed. Each scale is analyzed independently. In response to the Advisory Issue, we have included the unabbreviated titles of the scales, their minimum and maximum values, and clarified whether higher scores represent better or worse outcomes for each outcome measure.

    Within 6 weeks of treatment.

Secondary Outcomes (1)

  • Pelvic floor function

    Within 6 weeks of treatment.

Study Arms (2)

obese with ODS

ACTIVE COMPARATOR

BT PTNS in obese patients with ODS

Procedure: Bilateral posterior tibial nerve stimulation

Non obese with ODS

ACTIVE COMPARATOR

BT PTNS in non-obese patients with ODS

Procedure: Bilateral posterior tibial nerve stimulation

Interventions

* Procedure: BT PTNS will be administered via transcutaneous electrodes placed bilaterally along the posterior tibial nerve at the medial malleolus. * Frequency: 3 sessions per week for 6 weeks (total of 18 sessions). * Duration per Session: 30 minutes. * Monitoring: Patients will be monitored for adverse events during and after each session.

Non obese with ODSobese with ODS

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of functional obstructed defecation (Rome IV criteria).
  • Able to provide informed consent.
  • BMI ≥30 kg/m² (obese group) or BMI \<30 kg/m² (non-obese group).

You may not qualify if:

  • Organic causes of constipation (e.g., colorectal cancer, inflammatory bowel disease).
  • Previous pelvic floor surgery.
  • Neurological disorders affecting bowel function.
  • Pregnancy or lactation.
  • Current use of other neuromodulation therapies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The surgical department of Medical Research Institute Hospital, Alexandria University

Alexandria, 21531, Egypt

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of General surgery

Study Record Dates

First Submitted

December 23, 2025

First Posted

February 5, 2026

Study Start

February 15, 2026

Primary Completion

March 25, 2026

Study Completion

March 28, 2026

Last Updated

April 29, 2026

Record last verified: 2026-04

Locations